StreetInsider.com News Articles

Telo Genomics increases private placement to $1.6 million

Fri, 27 Feb 2026 15:34:12 +0000

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) announced it has increased the size of its previously announced private placement of convertible debentures from $1,200,000 to $1,600,000.

The debentures will carry a 15% annual interest rate, compounded quarterly, and mature on December 15, 2026. Holders can convert the principal amount into common shares at $0.05 per share before maturity. The company cannot prepay the debentures prior to the maturity date.

For every $100,000 of convertible debentures issued, the company will issue 2 million detachable warrants. Each warrant allows the purchase of one common share at $0.08 per share for 12 months from the

Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement

Fri, 27 Feb 2026 15:32:00 +0000

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has increased the size of its previously announced non-brokered private placement of non-transferable secured convertible debentures (the "Debentures") from up to $1,200,000 to up to $1,600,000 (the "Upsized Offering").

The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the "Maturity Date"). The principal

Telo Genomics Corp. Announces Upsizing of Previously Announced Private Placement

Fri, 27 Feb 2026 15:32:00 +0000

The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the "Maturity Date"). The principal

Telo Genomics Closes First Tranche of Convertible Debentures Financing

Wed, 18 Feb 2026 07:00:00 +0000

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Vancouver, British Columbia--(Newsfile Corp. - February 18, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement offering (the "Offering") of non-transferable secured convertible debentures ("Debentures") (see news release dated January 19, 2026) by issuing Debentures for gross proceeds

Telo Genomics Closes First Tranche of Convertible Debentures Financing

Wed, 18 Feb 2026 07:00:00 +0000

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Telo Genomics appoints John Price as chief financial officer

Thu, 29 Jan 2026 08:02:11 +0000

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) announced the appointment of John Price as chief financial officer, effective January 30, 2026, according to a press release statement.

Price brings over 30 years of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. His background includes executive positions at publicly traded companies such as Assure Holdings, National Beverage, Alliance MMA, and MusclePharm.

Price also held accounting and finance roles at technology companies in Silicon Valley, including Opera Software, GCT Semiconductor and Tessera Technologies. He began his career with seven years at Ernst & Young and holds a Bachelor of Science

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Thu, 29 Jan 2026 08:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - January 29, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Price has been appointed as Chief Financial Officer, effective immediately.

Mr. Price was appointed as Chief Financial Officer effective January 30, 2026. Mr. Price has over three decades of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. Mr. Price's prior experience includes executive positions in several public companies including Assure

Telo Genomics Announces Appointment of John Price as Chief Financial Officer

Thu, 29 Jan 2026 08:00:00 +0000

Telo Genomics plans private placement for up to $1.2 million

Mon, 19 Jan 2026 08:02:11 +0000

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) announced a non-brokered private placement offering of secured convertible debentures for gross proceeds of up to $1,200,000.

The debentures will carry a 15% annual interest rate, compounded quarterly, and mature nine months after closing. Holders may convert the principal amount into common shares at $0.05 per share before maturity. For every $100,000 of debentures issued, the company will provide 2 million detachable warrants, exercisable at $0.08 per share for 12 months from closing.

The company plans to use proceeds for lab trials and general working capital. The offering requires approval from the TSX Venture Exchange.

Securities

Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000

Mon, 19 Jan 2026 08:00:00 +0000

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") is pleased to announce a non-brokered private placement offering of secured convertible debentures ("Debentures") for gross proceeds of up to $1,200,000 (the "Offering"). The Company may pay finder's fees in connection with the Offering.

The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date (the "Maturity Date").

Telo Genomics Announces Non-Brokered Private Placement of Convertible Debentures for up to $1,200,000

Mon, 19 Jan 2026 08:00:00 +0000

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
OR FOR DISSEMINATION IN THE UNITED STATES

The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date (the "Maturity Date").

Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

Thu, 18 Dec 2025 16:05:00 +0000

Toronto, Ontario--(Newsfile Corp. - December 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced the initiation of a new multiple myeloma (MM) Minimal Residual Disease (MRD) clinical trial in collaboration with the University of Athens.

This retrospective study is a key component of Telo's expanding, multi-center MRD validation program and is designed to evaluate the clinical utility of Telo's blood-based TeloView®MRD. The University of Athens collaboration provides access to well-characterized clinical blood samples with retrospectively available patient outcomes and an average of

Telo Genomics Launches Retrospective Blood-Based MRD Study with University of Athens as Part of 2026 Multi-Center Validation Program

Thu, 18 Dec 2025 16:05:00 +0000

Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Thu, 11 Dec 2025 16:00:00 +0000

Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with a poster presentation during the 67^th American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

The poster presentation describes the initial clinical results of a new MRD evaluation that combines the enumeration of individual MM Circulating Tumor Cells (CTCs) from peripheral blood with the

Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting

Thu, 11 Dec 2025 16:00:00 +0000

The poster presentation describes the initial clinical results of a new MRD evaluation that combines the enumeration of individual MM Circulating Tumor Cells (CTCs) from peripheral blood with the

Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing

Wed, 10 Dec 2025 09:57:00 +0000

NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Small Cap Growth Virtual Investor Conference, held December 9th, are now available for online viewing.

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company’s resource section.

Select companies are accepting 1x1 management meeting requests through December 16th.